InvestSMART

BLS Pharmaceuticals Limited (ASX:BLS)

ALERT: Price-sensitive ASX Announcement for BLS
Current share price for BLS : $0.935 0.095 (11.31%)+
Announcement
Release
27 Jul 2026 8:52AM
Price at Release
$0.840
Full Release
download
Summary
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, reported significant financial and operational achievements in its Quarterly Activities Report for the period ending 30 June 2026. The company recorded a quarterly revenue of $22.5 million, marking a 5% increase over the previous quarter, and a FY26 revenue of $74.98 million, which is a 156% increase from the prior year. BLS reported positive operating cash flow of $6.3 million and cash receipts of $20.7 million for the quarter. The cash balance rose to $13.3 million. Notably, BLS secured a $50 million supply agreement with ADREXpharma in Germany and expanded into the Costa Rican market. The company also strengthened its board by appointing Edward Myer as an independent Non-Executive Director and completed its corporate transition to BLS Pharmaceuticals Limited. These developments underscore BLS's continued growth and expansion into international regulated markets.
Key Points
  • Record quarterly revenue of $22.5 million, 5% increase from previous quarter.
  • FY26 revenue of $74.98 million, 156% increase from prior year.
  • Positive operating cash flow of $6.3 million for the quarter.
  • Cash receipts of $20.7 million for the quarter and $72.9 million for FY2026.
  • Cash balance increased to $13.3 million at 30 June 2026.
  • Two-year $50 million pharmaceutical supply agreement with ADREXpharma in Germany.
  • First international supply of medicinal cannabis flower to Costa Rica.
  • Appointment of Edward Myer as independent Non-Executive Director.
  • Completion of transition to BLS Pharmaceuticals Limited.
  • Major international commercial partnerships and entry into new regulated markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.